Insulin degludec

(Tresiba®)

Insulin degludec

Drug updated on 5/17/2024

Dosage FormInjection (subcutaneous; 300 units/3 mL, 600 units/3 mL, 1000 units/10 mL)
Drug ClassInsulin analogs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Insulin degludec (Tresiba) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. It demonstrates comparable efficacy to insulin glargine regarding the mean change in HbA1c levels and incidence rates of hypoglycemia but offers superior reduction in fasting plasma glucose.
  • The analysis was based on a review of 19 systematic reviews/meta-analyses focused on Tresiba's safety and effectiveness compared to other insulin analogues across various patient populations.
  • When combined with GLP-1 receptor agonist liraglutide (IDegLira), insulin degludec shows significant improvements in glycemic control for Type 2 Diabetes patients, including better HbA1c reduction without weight gain or severe hypoglycemia.
  • Compared to newly introduced ultra-long-action basal insulins like Insulin Icodec, Tresiba has shown superior efficacy, particularly when considering HbA1C reduction and safety profiles according to subgroup analyses.
  • Across different patient populations such as those with Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D), Tresiba generally presents a favorable safety profile by reducing the risk of hypoglycemia compared to other insulin analogs like Glargine and Detemir.
  • Several studies suggest that Tresiba may be less likely than other therapies to cause weight gain while offering convenient dosing regimens that could potentially enhance overall management of diabetes.
  • The drug's benefits extend from adolescent through elderly patients, indicating its broad applicability for both Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).
  • Specific comparisons between Tresiba (Insulin Degludec) and drugs such as IGlar-300 or novel Insulin Icodec reveal nuanced differences that might guide personalized treatment decisions, especially concerning hypoglycemia risk and dosing frequency preferences.

Product Monograph / Prescribing Information

Document TitleYearSource
Tresiba (insulin degludec) Prescribing Information.2022Novo Nordisk Inc., Plainsboro, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis.2024Frontiers in Endocrinology
IDegLira for type 2 diabetes: a systematic review and meta-analysis.2024Endocrine
Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.2024Diabetes/Metabolism Research & Reviews
Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: a meta-analysis of ONWARDS phase 3 randomized controlled trials.2024Diabetes, Obesity & Metabolism
Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.2024Frontiers in Endocrinology
Use of basal insulin in the management of adults with type 2 diabetes: an Asia-Pacific evidence-based clinical practice guideline.2023Journal of Diabetes
Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: a systematic review with meta-analysis.2023Journal of Diabetes
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.2023Diabetes, Obesity & Metabolism
Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials.2022Diabetes & Metabolic Syndrome
Efficacy and safety of insulin degludec/insulin Aspart (IDegAsp) in type 2 diabetes: systematic review and meta-analysis.2022Cureus
Efficacy and tolerability of insulin degludec versus other long-acting basal insulin analogues in the treatment of type 1 and type 2 diabetes mellitus: a systematic review and meta-analysis.2022Clinical Therapeutics
Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.2022International Journal of Clinical Pharmacy
Insulin degludec versus insulin glargine on glycemic variability in diabetic patients: a systematic review and meta-analysis of randomized controlled trials.2022Frontiers in Endocrinology
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.2021The Cochrane Database of Systematic Reviews
Efficacy and safety of iGlarLixi versus IDegAsp: results of a systematic literature review and indirect treatment comparison.2021Diabetes, Obesity & Metabolism
Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.2021Naunyn-Schmiedeberg’s Archives of Pharmacology
Safety and efficacy of long-acting insulins degludec and glargine among Asian patients with type 2 diabetes mellitus: a meta-analysis.2021Cureus
(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.2020The Cochrane Database of Systematic Reviews
Comparative effectiveness and harms of long-acting insulins for type 1 and type 2 diabetes: a systematic review and meta-analysis.2019Diabetes, Obesity & Metabolism
Insulin degludec, a novel ultra-long-acting basal insulin versus insulin glargine for the management of type 2 diabetes: a systematic review and meta-analysis.2019Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders